|
Match
|
Document |
Document Title |
|
|
8183340 |
GLP-1 pegylated compounds
The invention provides GLP-1 compounds coupled to two polyethylene glycol molecule or derivative thereof, resulting in a biologically active peptide with an extended half-life and a slower...
|
|
|
8158579 |
Fusion protein of an exendin to modified transferrin
The invention provides fusion proteins comprising an exendin-4 fused to a transferrin (Tf) via a polypeptide linker, as well as corresponding nucleic acid molecules, vectors, host cells, and...
|
|
|
8158125 |
B-cell epitope peptides of HSP 65, novel amino acid sequences, DNA encoding the amino acid sequences of said peptides, antibodies directed against said peptides and different uses thereof in the treatment of inflammatory and autoimmune diseases
B-cell epitope peptides of HSP 65, particularly the peptides comprising the amino acid sequence substantially as denoted by SEQ ID: NOs. 1-5 and their biologically functional homologues and...
|
|
|
8153583 |
Toll like receptor 3 antagonists, methods and uses
Toll Like Receptor 3 (TLR3) antagonists, polynucleotides encoding TLR3 antagonists, and methods of making and using the foregoing are disclosed.
|
|
|
8143217 |
Use of DPP-IV inhibitor to reduce hypoglycemic events
The invention relates to a method to reduce the hypoglycemic events, especially sever hypoglycemic events resulting from insulin treatment, wherein the patient is treated with a Dipeptidyl...
|
|
|
8129339 |
Microencapsulation and sustained release of biologically active polypeptides
The invention relates to compositions and methods for the sustained release of biologically active polypeptides. The sustained release compositions of this invention comprise a biocompatible...
|
|
|
8119591 |
Methods and compositions for regenerating articular cartilage
Methods and compositions are described to regenerate cartilage in a partial thickness defect or area of reduced volume of articular cartilage comprising an infiltration suppressor agent and a...
|
|
|
8119593 |
Method of treating diabetes type 2 by metformin and an ultrarapid acting insulin
Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin,...
|
|
|
8114837 |
Method for inhibiting postprandial rise in blood glucose by administering κ-casein
The invention relates to a GLP-1 secretagogue and an inhibitor of postprandial rise in blood glucose, containing κ-casein as an active ingredient, and a food or drink for promoting GLP-1 secretion ...
|
|
|
8097586 |
Modified exedins and uses thereof
Novel exendins with modifications at one or more of following positions: 2, 14, 27 or 28 and polyethylene glycol derivatives thereof are provided. These compounds are useful in treating type 2...
|
|
|
8088727 |
Method for reducing the risk, lessening the symptom, or delaying the onset of insulin resistance by administering SS-31
The invention provides methods of preventing or treating insulin resistance in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic...
|
|
|
8084422 |
Method of treating insulin resistance with a selective inhibitor of CB2 receptor activity
The invention relates to the use of a selective inhibitor of CB2 receptor expression and/or for the manufacture of a medicament indented for the treatment and/or the prevention of obesity and...
|
|
|
8084420 |
Rapid acting and long acting insulin combination formulations
An injectable formulation containing a rapid acting insulin and a long acting insulin has been developed. The pH of the rapid acting insulin is adjusted so that the long acting insulin, remains...
|
|
|
8080523 |
Analogs of ShK toxin and their uses in selective inhibition of Kv1.3 potassium channels
Analogs of ShK toxin and methods for using such ShK analogs. The ShK analogs generally comprise ShK toxin attached to a chemical entity (e.g. an atom, molecule, group, residue, compound, moiety,...
|
|
|
8076282 |
Composition for improving membrane composition and functioning of cells
It has now been found that after administration to a diseased person or person that is at risk for developing such disease of a neutraceutical or pharmaceutical composition that comprises a/ a...
|
|
|
8057822 |
Modified exendins and exendin agonists
Novel modified exendins and exendin agonists having an exendin or exendin agonist linked to one or more polyethylene glycol polymers, for example, and related formulations and dosages and methods...
|
|
|
8044020 |
Pharmaceutical compositions and methods for insulin treatment
Compositions and methods for treating a patient with insulin that combines insulin, a permeation enhancer, and a carrier that maintains an acidic pH, are disclosed.
|
|
|
8039432 |
Method of treatment of diabetes and/or obesity with reduced nausea side effect
The present invention provides methods of administering an insulinotropic peptide in an amount effective to treat a disorder or condition while reducing nausea side effect by administering to a...
|
|
|
8022035 |
Y4 selective receptor agonists for therapeutic interventions
Y4 receptor agonist peptide selected from the group consisting of: [Ala30]PP2-36, [Thr30]PP2-36, [Asn30]PP2-36, [Gln30]PP2-36, [Glu10]PP2-36, [Glu10,Leu17,Thr30]PP2-36, [Nle17,Nle30]PP2-36,...
|
|
|
8017573 |
Adiponectin receptor fragments and methods of use
Methods are disclosed of treating diabetes, abnormal adipocyte activity, and insulin resistance using C-terminal fragments of adiponectin receptor R1. Methods of causing the secretion of insulin in...
|
|
|
8008436 |
Adenovirus 36 E4 orf 1 gene and protein and their uses
Expression of the E4 orf 1 gene of Ad-36 alone has been discovered to be responsible for the increased insulin sensitivity observed in Ad-36 infected animals, including increased adipogenesis....
|
|
|
8003606 |
Inhibiting serum response factor (SRF) to improve insulin sensitivity
Described are methods of improving glycemic control/improving insulin sensitivity by administering an inhibitor of serum response factor (SRF) activity, and methods of identifying new compounds for...
|
|
|
7998928 |
Method of treatment of type-1 diabetes with a humanin analogue
The present invention is based on the discovery that Humanin and humanin analogues protect pancreatic beta cells in vitro and in vivo from apoptosis. Accordingly, humanin and its analogues are...
|
|
|
7985730 |
3-aminopyrrolidine derivatives as modulators of chemokine receptors
The present invention relates to 3-aminopyrrolidine derivatives of the formula I: (wherein R1, R2, R3, R4, R5, R6, R7, R8, X, Y and X are as defined herein) which are useful as modulators of...
|
|
|
7964558 |
Therapeutic applications for C-peptide
The present invention relates to administration of C-peptide in a once daily dose for use in the treatment of diabetes and diabetic complications.
|
|
|
7959956 |
Method for treating diabetic complications
The present invention relates to a method for treating diabetic complications, which comprises administering an extract obtained by: crashing and drying any one selected from Euphorbiae radix,...
|
|
|
7956035 |
Treatment of endothelial dysfunction in diabetic patients
A method for the treatment of endothelial dysfunction in a diabetic patient, including both diabetes induced macrovascular disorders and diabetes induced microvascular disorders, comprises...
|
|
|
7939114 |
Preparation, process and a regenerative method and technique for prevention, treatment and glycemic control of diabetes mellitus
A medicinal preparation, a process, a nutritional composition and regenerative and insulin potentiating method for humans and also for mammals for prevention, treatment and management/glycemic...
|
|
|
7928060 |
Amylin family polypeptide-6 (AFP-6) analogs and methods of making and using them
The present invention relates to Amylin Family Polypeptide-6 (AFP-6) analogs, which include derivatives and fragments, related nucleic acids, expression constructs, host cells, and processes for...
|
|
|
7897572 |
Theraputic methods for type I diabetes
The invention relates to the treatment and prevention of type I diabetes. More specifically, the invention relates to compounds that treat or prevent the body's immune system from destroying...
|
|
|
7855177 |
Methods and kits for preventing hypoglycemia
Improved methods and kits for treating the long-term complication of diabetes that reduce the risk of the patient developing hypoglycemia during C-peptide therapy. The use of such methods and kits,...
|
|
|
7833982 |
Methods of treating dermal ulcers with thrombin derived peptides
Disclosed is a method of promoting healing of a chronic dermal skin ulcer, such as a diabetic ulcer, on a subject. The method comprises the step of contacting the chronic dermal skin ulcer with an...
|
|
|
7829534 |
Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant molecules
The present invention is a method of inhibiting islet cell transplant rejection particular, to treat diabetes, such as type-1 and type-2 diabetes, by administering to a subject an effective amount...
|
|
|
7829530 |
Method of regulating glucose metabolism, and reagents related thereto
One aspect of the present invention relates to a method for treating Type II diabetes in an animal, comprising conjointly administering to the animal metformin and an inhibitor of...
|
|
|
7816325 |
Secondary binding site of dipeptidyl peptidase IV (DP IV)
The present application relates to the secondary binding site of dipeptidyl peptidase IV, its relationship amongst substrates and to the modulation of substrate specificity of dipeptidyl peptidase...
|
|
|
7811987 |
Methods for reducing CD36 expression
The invention provides a method for reducing CD36 expression in a cell. The method comprises contacting the cell with an effective amount of an aromatic-cationic peptide having at least one net...
|
|
|
7807622 |
Composition and use of phyto-percolate for treatment of disease
This invention relates generally to a method of preparation of a phyto-percolate that is derived from fresh water mixture including algae. The phyto-percolate is believed to contain an enzyme...
|
|
|
7807623 |
Use of pentagastrin to inhibit gastric acid secretion or as a diuretic
This invention pertains to the discovery administration of a CCK receptor agonist can increase urinary sodium excretion and/or free water excretion in a mammal. CCK receptor agonist can thereby be...
|
|
|
7799760 |
Use of pharmaceutical composition containing epidermal growth factor (EGF) for diabetic foot amputation prevention
The invention relates to the use of Epidermal Growth Factor (EGF) in a preferably-injectable pharmaceutical composition which is administered by means of infiltration into and around chronic...
|
|
|
7799755 |
Immunomodulatory methods using oligosaccharides
Methods for modulating immune responses are provided. The methods involve contacting an immune cell with an agent that modulates interaction of a compound comprising a Lewis antigen with the immune...
|
|
|
7763580 |
Methods for treating conditions associated with the accumulation of excess extracellular matrix
The present invention is methods and compositions for reducing and preventing the excess accumulation of extracellular matrix in a tissue and/or organ or at a wound site using a combination of...
|
|
|
7759398 |
Methods for modulating metabolism
The subject invention provides materials and methods for modulating a variety of biological factors to treat biological conditions associated with the factors. In one embodiment of the invention, a...
|
|
|
7745387 |
Use of erythropoietin
The present invention relates to the use of erythropoietin for stimulating the physiological mobilization, proliferation and differentiation of endothelial progenitor cells, for stimulating...
|
|
|
7741269 |
Exendins and exendin agonists for weight reduction and obesity
Methods for treating conditions or disorders which can be alleviated by reducing food intake are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist,...
|
|
|
7741085 |
Compound WS727713
The present invention relates to a compound WS727713, useful as a modulator of melanocortin receptors, and a process for its production by culturing in a culture medium the actinomycetes strain of...
|
|
|
7741274 |
Casein derived peptides and uses thereof in therapy
Biologically active peptides that are derived from or are similar to sequences identical with the N-terminus of the oS1 fraction of milk casein. These peptides are capable of stimulating and...
|
|
|
7737116 |
Modified and stabilized GDF propeptides and uses thereof
Modified and stabilized propeptides of Growth Differentiation Factor proteins, such as GDF-8 and Bone Morphogenetic Protein-11, are disclosed. Also disclosed are methods for making and using the...
|
|
|
7737113 |
Antiarrhythmic peptides
Disclosed are novel peptides including antiarrhythmic peptides that have improved stability. Further disclosed are compositions that include such peptides and methods of using the compositions...
|
|
|
7732400 |
Method for inhibiting new tissue growth in blood vessels in a patient subjected to blood vessel injury
This invention provides for a method for inhibiting new tissue growth in blood vessels in a subject, wherein the subject experienced blood vessel injury, which comprises administering to the...
|
|
|
7709440 |
Treating neoplasms with neurotoxin
The present invention provides a method of treating a cancer using a neurotoxin, preferably Botulinum toxin (“BTX”). The application of a neurotoxin around a cancer acts to decrease the con...
|